Unlocked: Elon Musk’s Next Big IPO (from Brownstone Research)
Key Points
Exxon Mobil trades at a higher forward P/E than Nvidia, signaling a shift.
Goldman Sachs sees ~51% upside despite weakness.
Nvidia is shifting into a stable AI infrastructure utility.
Growth is moving to Marvell Technology and Recursion Pharmaceuticals.
NVIDIA’s $1 Trillion Superproject: Get the Inside Scoop (from Weiss Ratings)
Three months ago, the idea that Exxon Mobil would trade at a higher forward P/E than Nvidia seemed absurd, yet Benzinga data confirms a 22.3x multiple for XOM against 21.4x for NVDA as of April 1, highlighting a nuanced market shift where earnings expectations for Nvidia are surging while its multiple compresses. This convergence signals a structural change where Nvidia remains a dominant growth story with high visibility, while the explosive growth potential migrates to partners like Marvell, which received a $2 billion investment, and adopters like Recursion Pharmaceuticals, whose AI tools now cut clinical trial entry times from 42 to 17 months.
The Price vs. Target Divergence
Goldman Sachs' recent $250 price target for Nvidia implies a 51% upside from current levels, despite the stock hovering near $140 support after sliding from $170. This divergence between market psychology and professional valuation reveals a critical disconnect. While the market grapples with short-term volatility, analysts remain bullish on Nvidia's long-term potential, citing strong demand for its AI chips and the company's strategic investments in AI infrastructure.
Presented by Brownstone Research:
“NVIDIA’s Magnificent 7”
Tech legend Jeff Brown – the Silicon Valley insider who called NVIDIA in 2016 before it skyrocketed over 30,000...
...has uncovered seven NVIDIA partner stocks set to explode after Jensen Huang's big announcement as early as May 20, 2026.
Handing early investors a once-in-a-lifetime chance to pocket generational wealth in America's FINAL AI boom.
The Utility Shift
As Benzinga noted, Nvidia's earnings are finally catching up to the stock price. This shift from hype to hard infrastructure reflects a broader market trend where AI is evolving from a speculative growth story to a stable utility.
Nvidia, once seen as a high-growth, speculative stock, is increasingly viewed as a reliable income generator. This transformation is evident in the company's financials, where consistent revenue growth and profitability are becoming the new benchmarks.
Where the Growth Actually Is
Goldman Sachs' healthcare thesis highlights a transformative shift in the biotech sector, where artificial intelligence is revolutionizing drug development. Recursion Pharmaceuticals, the pioneer mentioned earlier, has demonstrated this power by reducing the average time to enter human trials from 42 months to just 17 months.
Meanwhile, Nvidia's investment in Marvell Technology to build AI factories signals that the networking layer of AI infrastructure is where capital is flowing next.
Why Pure NVDA Exposure Misses the Picture
This transition from speculative growth to infrastructure utility is not without risks, however. As Yahoo Finance highlighted, Nvidia's DLSS 5 technology has sparked backlash, with users viewing it as an "AI slop filter" that adds unwanted artificial realism to games.
This reaction serves as a microcosm of the broader friction that can arise when AI adoption outpaces consumer readiness.
Stay calm. Stay focused.
Further Reading
New way to crush the market by trading in your sleep (from Millionaire Publishing)
The hidden opportunity inside the gold bull market. (from Weiss Ratings)
Subscribe to ETF Alert for real-time market news.
We track the trends that move billions, before they hit mainstream headlines.
[Subscribe to ETF Alert]
Disclaimer: This is not financial or investment advice. Do your own research and consult a qualified financial advisor before investing.